Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01948232
Other study ID # 1000035483
Secondary ID
Status Withdrawn
Phase Phase 2
First received September 18, 2013
Last updated October 2, 2015
Start date September 2013
Est. completion date July 2015

Study information

Verified date October 2015
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the feasibility of conducting a medical intervention trial in childhood cancer survivors with early echocardiographic evidence of cardiac remodeling.


Description:

Anthracycline cardiotoxicity is characterized by ventricular remodeling and progressive cardiac dysfunction. Since ventricular remodeling in other types of heart failure can be treated effectively with an angiotensin-converting enzyme inhibitor (ACEi), these agents would appear a logical therapy in children with anthracycline-induced heart failure. Previous experience with ACEi in childhood cancer survivors has shown mixed results, possibly due to the fact that treatment is initiated too late in the natural history of the disease. Providing treatment in childhood cancer survivors with early signs of cardiac remodeling may be more effective than treating children who have global dysfunction. The benefits of early intervention are unclear, so it is unclear whether CCS and their parents will be willing to receive treatment where the target outcome (prevention of decreased global function or congestive heart failure) may not occur for years after the intervention. Assessing the feasibility of this pre-emptive approach is the primary aim of the study.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group N/A to 20 Years
Eligibility Inclusion Criteria:

1. Enrolled in the Survivor Cohort of the PCS2 study at The Hospital for Sick Children at the time of enrollment.

2. Aged < 20 years at enrollment.

3. Weight = 25kg at enrollment

4. LVPW Z-score =-2.0 at any of the 0, 12 or 24 month PCS2 echocardiography assessments, on two consecutive echocardiograms at least 3 but no more than 15 months apart.

5. EF greater than 50% at enrollment

6. Serum potassium (to be ?5.0mMol/l) at Initiation

Exclusion Criteria:

1. Known associated cardiac conditions for which angiotensin converting enzyme therapy is contraindicated (such as aortic stenosis, severe coarctation of the aorta, or hypertrophic cardiomyopathy with LV outflow tract obstruction)

2. Active malignancy detected within last 2 years (i.e. must be at least 2 years in remission)

3. Prior radiation therapy to a field that involved the heart

4. Prior symptomatic heart failure, or prior reduction in EF below 50% detected on surveillance echocardiography.

5. Use of any cardioactive medications including diuretics within the last 6 months

6. Concurrent serious or life threatening disease or extracardiac organ compromise which would limit participation in the trial or potentially have secondary effects on cardiac function, as determined by the treating physician.

7. Renal dysfunction precluding ACEi therapy, defined as serum creatinine greater than the 95th percentile for age or eGFR by the modified Schwartz formula of less than the 5th percentile prior to recruitment to the interventional trial (within 30 days of recruitment date)

8. Hypertension requiring treatment.

9. History of angioedema or ACEi hypersensitivity

10. Patients with hereditary problems of galactose intolerance, glucose-galactose malabsorption, or the Lapp lactase deficiency.

11. Upper airway obstructive lesions

12. Pregnancy

13. Breast-feeding

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Perindopril
Angiotensin converting enzyme inhibitor

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
The Hospital for Sick Children

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients consenting to study The number of eligible patients approached to join the study, the proportion consenting to the study, the proportion refusing the study (with reasons for refusal) and the proportion remaining on study at 18-months. 18-month No
Secondary LV wall thinning Rate of change of the end-diastolic left ventricular posterior wall z-score and of the thickness to dimension ratio z-score 18 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05562193 - Exercise and Pain in CCS N/A
Completed NCT04075734 - Feasibility of a Self-Management + Peer Mentoring Intervention for Adolescent and Young Adult Childhood Cancer Survivors N/A
Completed NCT05641636 - Cardiovascular Disorders and Risk Factors in Childhood Cranial and Craniospinal Tumors Survivors
Recruiting NCT02355340 - Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
Recruiting NCT05527392 - Virtual Health Insurance Navigation Pilot Program for Childhood Survivors (HINTII) N/A
Completed NCT04947709 - Physical Activity Post-Cancer for Adolescents and Young Adults N/A
Completed NCT04520061 - Developing a Health Insurance Navigation Program for Survivors of Childhood Cancer N/A
Recruiting NCT03523377 - Overnight Fasting After Completion of Therapy: The OnFACT Study N/A
Recruiting NCT05463796 - InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer